WuXi Biologics (Cayman) Inc represents a strong set of values and a clear corporate philosophy. The company is committed to enabling global partners to develop and manufacture biologics efficiently and cost-effectively. WuXi Biologics is driven by a customer-centric approach, providing integrated solutions and the highest quality services to meet the diverse needs of its clients. With a focus on innovation, WuXi Biologics embraces cutting-edge technologies and invests in state-of-the-art facilities to ensure world-class bio-manufacturing capabilities. This dedication to excellence, along with a commitment to collaboration and integrity, positions WuXi Biologics as a trusted and leading player in the biopharmaceutical industry.

WuXi Biologics (Cayman) Inc is primarily present in China, with its headquarters in Shanghai. However, the company also has a global presence, with operations and facilities in multiple countries and regions. These include the United States, Germany, Ireland, Singapore, and China's Suzhou, Wuxi, and Hangzhou cities. With its international reach, WuXi Biologics (Cayman) Inc is well-positioned to cater to the global demand for biologics development, manufacturing, and supply chain solutions.

WuXi Biologics (Cayman) Inc, a leading global open-access biologics technology platform company, has achieved significant milestones since its inception. The company has rapidly expanded its capabilities and established strategic partnerships with global pharmaceutical giants. WuXi Biologics has successfully developed and launched numerous innovative biologics products, providing customized and high-quality solutions to its clients. Moreover, the company has received numerous accolades and recognition for its outstanding performance and contributions to the biopharmaceutical industry. Through its dedication to innovation and commitment to excellence, WuXi Biologics (Cayman) Inc continues to revolutionize the biologics landscape and drive advancements in healthcare.

WuXi Biologics (Cayman) Inc, founded in 2011, is a leading global open-access Biologics technology platform company. It offers end-to-end solutions for biologics discovery, development, and manufacturing to support worldwide partners in advancing biologics through various stages of development. With state-of-the-art facilities and a team of experienced professionals, WuXi Biologics leverages its expertise in cell line development, process development, and biologics manufacturing to offer cost-effective and high-quality services. The company's commitment to innovation, quality, and customer satisfaction has propelled its rapid growth and success in the biopharmaceutical industry. WuXi Biologics (Cayman) Inc is dedicated to enabling global healthcare by providing access to biologics for patients worldwide.

The main competitors of WuXi Biologics (Cayman) Inc in the market include companies such as Lonza Group Ltd., Catalent Inc., and Samsung Biologics Co., Ltd.

WuXi Biologics (Cayman) Inc primarily operates in the biopharmaceutical industry.

WuXi Biologics (Cayman) Inc. operates as a global open-access biologics technology platform company. It provides a comprehensive range of services in discovery, development, and manufacturing of biologics. The company's business model focuses on offering end-to-end solutions to global pharmaceutical and biotech companies. WuXi Biologics offers integrated services encompassing cell line development, process development, analytical development, and biologics manufacturing, including clinical and commercial manufacturing. By providing high-quality and cost-effective solutions, WuXi Biologics has established itself as a leading player in the biologics industry, enabling its clients to accelerate their drug development programs and reduce manufacturing costs.

KGV-d ei saa praegu WuXi Biologics (Cayman) jaoks arvutada.

KUV-d ei ole võimalik hetkel WuXi Biologics (Cayman) jaoks arvutada.

AlleAktien kvaliteediskoor ettevõttele WuXi Biologics (Cayman) on 4/10.

Praegu ei saa WuXi Biologics (Cayman) käivet arvutada.

Praegu ei ole võimalik kasumit WuXi Biologics (Cayman) jaoks arvutada.

The company WuXi Biologics (Cayman) Inc is a worldwide leading provider of end-to-end solutions in the biopharmaceutical industry. The company specializes in the manufacturing of biological drugs and offers a wide range of services, from research and development to manufacturing and marketing of products. WuXi Biologics' business model is divided into three main areas: 1. Research and Development: The company offers a comprehensive range of services for biopharmaceutical research and development, including protein and antibody structure elucidation, biomarker identification, cell line development, and small molecule production. WuXi Biologics aims to support its customers in accelerating their research process, thereby shortening the timeframe for product availability in the market. 2. Manufacturing: WuXi Biologics is one of the world's largest providers of manufacturing services for biological drugs. The company has a broad range of technologies and capabilities to meet its customers' requirements, from non-clinical to commercial product manufacturing. WuXi Biologics' production facilities are certified by the FDA or EMA, and the company strives to meet the highest standards in production and compliance with quality controls. 3. Marketing and Distribution: WuXi Biologics also offers marketing and distribution services for biological drugs, including support in product launch and management of distribution networks. The company has an experienced team of industry analysts, market researchers, and sales experts who help customers maximize their market presence and increase profits. The products offered by WuXi Biologics include biologicals, small molecules, and sample preparation, such as antibodies, peptides, recombinant proteins, and oligonucleotides. The company also provides platform technologies such as CHO-S production, plasmid manufacturing, virus production, proteomic analysis, and clinical diagnostics. With its innovative technologies, wide range of services, and ability to collaborate with customers worldwide, WuXi Biologics has firmly established its reputation as a leading company in the biopharmaceutical industry.

WuXi Biologics (Cayman) maksab dividendi 0 CNY, mis jaotatakse väljamakse peale aasta jooksul.

Dividendi ei saa praegu WuXi Biologics (Cayman) jaoks arvutada või ettevõte ei maksa dividende välja.

WuXi Biologics (Cayman) ISIN on KYG970081173.

WuXi Biologics (Cayman) WKN on A2QJCN.

WuXi Biologics (Cayman) tähis on 2269.HK.

Viimase 12 kuu jooksul maksis WuXi Biologics (Cayman) dividendi suuruses . See vastab ligikaudu dividenditootlusele. Järgneva 12 kuu jooksul maksab WuXi Biologics (Cayman) tõenäoliselt dividendi summas 0 CNY.

WuXi Biologics (Cayman) praegune dividenditootlus on .

WuXi Biologics (Cayman) maksab kvartaalset dividendi. See makstakse välja kuudel .

WuXi Biologics (Cayman) maksis viimase 0 aasta jooksul igal aastal dividendi.

Järgmise 12 kuu jooksul oodatakse dividende summas 0 CNY. See vastab dividenditootlusele 0 %.

WuXi Biologics (Cayman) on liigitatud sektorisse 'Tervis'.

Viimase WuXi Biologics (Cayman) dividendide saamiseks 15.1.2025 suuruses 0 CNY pidid sul olema aktsiaid portfellis enne eks-dividendi päeva 15.1.2025.

Viimane dividendimakse toimus 15.1.2025.

Aastal 2024 maksis WuXi Biologics (Cayman) 0 CNY dividende.

WuXi Biologics (Cayman) dividendid makstakse välja CNY.